209 related articles for article (PubMed ID: 33159794)
1. The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids.
Persson R; Hagberg KW; Qian Y; Vasilakis-Scaramozza C; Jick S
Rheumatology (Oxford); 2021 Apr; 60(4):1926-1931. PubMed ID: 33159794
[TBL] [Abstract][Full Text] [Related]
2. Psoriatic arthritis risk in psoriasis patients prescribed acitretin versus disease-modifying antirheumatic drugs: a nationwide cohort study.
Lin TL; Chang YL; Ho HJ; Chen YJ; Wu CY
Rheumatology (Oxford); 2024 May; 63(6):1624-1631. PubMed ID: 37656926
[TBL] [Abstract][Full Text] [Related]
3. Cycling or swap biologics and small molecules in psoriatic arthritis: Observations from a real-life single center cohort.
Ariani A; Santilli D; Mozzani F; Lumetti F; Lucchini G; Di Donato E; Giordano S; Riva M; Becciolini A
Medicine (Baltimore); 2021 Apr; 100(16):e25300. PubMed ID: 33879661
[TBL] [Abstract][Full Text] [Related]
4. Cause analysis of conversion to biologics in spondyloarthritis patients with poor response to conventional treatment.
Zhou J; Huang W; Zhang Z; Luo L; Ren F; Huang D; Tang L
Clin Rheumatol; 2023 Dec; 42(12):3251-3255. PubMed ID: 37740841
[TBL] [Abstract][Full Text] [Related]
5. Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review.
Dal Bello G; Gisondi P; Idolazzi L; Girolomoni G
Rheumatol Ther; 2020 Jun; 7(2):271-285. PubMed ID: 32306243
[TBL] [Abstract][Full Text] [Related]
6. Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice.
Caldarola G; Mariani M; Pirro F; Nicolotti N; Burlando M; Calabrese L; Parodi A; Peris K; De Simone C
Expert Opin Biol Ther; 2021 Feb; 21(2):279-286. PubMed ID: 33170052
[No Abstract] [Full Text] [Related]
7. Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results.
Ogdie A; Liu M; Glynn M; Emeanuru K; Harrold LR; Richter S; Guerette B; Mease PJ
J Rheumatol; 2021 May; 48(5):693-697. PubMed ID: 33191289
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
Smolen JS; Sebba A; Ruderman EM; Schulze-Koops H; Sapin C; Gellett AM; Sprabery AT; Li L; de la Torre I; Gallo G; Liu-Leage S; Pillai S; Reis P; Nash P
Rheumatol Ther; 2020 Dec; 7(4):1021-1035. PubMed ID: 33200394
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience.
Bonifati C; Morrone A; Cristaudo A; Graceffa D
Dermatol Ther; 2021 Jan; 34(1):e14584. PubMed ID: 33236471
[TBL] [Abstract][Full Text] [Related]
10. Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone.
Brazzelli V; Isoletta E; Barak O; Barruscotti S; Vassallo C; Giorgini C; Michelerio A; Tomasini CF; Musella V; Klersy C
Dermatol Ther; 2020 Nov; 33(6):e14516. PubMed ID: 33169500
[TBL] [Abstract][Full Text] [Related]
11. Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis.
Yamaguchi Y; Kanai Y; Kitabayashi H; Okada H; Nakagawa H
J Dermatol; 2021 Mar; 48(3):324-333. PubMed ID: 33161605
[TBL] [Abstract][Full Text] [Related]
12. The value of subcutaneous vs. oral methotrexate: real-world data from the German psoriasis registry PsoBest.
Reich K; Sorbe C; Griese L; Reich JLK; Augustin M
Br J Dermatol; 2021 Apr; 184(4):765-767. PubMed ID: 33220078
[No Abstract] [Full Text] [Related]
13. Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study.
Atalay S; van den Reek JMPA; Otero ME; Njoo MD; Mommers JM; Ossenkoppele PM; Koetsier MI; Berends MM; van de Kerkhof PCM; Groenewoud HMM; den Broeder AA; de Jong EMGJ; Kievit W
Acta Derm Venereol; 2020 Dec; 100(19):adv00340. PubMed ID: 33196101
[TBL] [Abstract][Full Text] [Related]
14. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience.
Gisondi P; Piaserico S; Naldi L; Dapavo P; Conti A; Malagoli P; Marzano AV; Bardazzi F; Gasperini M; Cazzaniga S; Costanzo A;
J Allergy Clin Immunol; 2021 Feb; 147(2):558-560.e1. PubMed ID: 33160968
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.
Letarouilly JG; Flachaire B; Labadie C; Kyheng M; Cohen N; Sellam J; Richette P; Dieude P; Claudepierre P; Fautrel B; Houvenagel E; Nguyen CD; Guyot MH; Segaud N; Marguerie L; Deprez X; Salmon JH; Baudens G; Miceli-Richard C; Gervais E; Chary-Valckenaere I; Lafforgue P; Philippe P; Loeuille D; Richez C; Tubach F; Pham T; Flipo RM
Rheumatology (Oxford); 2021 Jun; 60(6):2773-2782. PubMed ID: 33232465
[TBL] [Abstract][Full Text] [Related]
16. Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors.
Yeung J; Vender R; Turchin I; Shukla R; Maari C; Hong CH; Barakat M; Lansang P
J Am Acad Dermatol; 2021 Apr; 84(4):1169-1171. PubMed ID: 33221464
[No Abstract] [Full Text] [Related]
17. Ixekizumab in the treatment of psoriatic arthritis.
Lespessailles E; Toumi H
Immunotherapy; 2021 Jan; 13(1):19-33. PubMed ID: 33167745
[TBL] [Abstract][Full Text] [Related]
18. Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience.
De A; Das S; Dhoot D; Sarda A
Indian J Dermatol; 2020; 65(5):396-400. PubMed ID: 33165422
[TBL] [Abstract][Full Text] [Related]
19. Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies.
Galluzzo M; Talamonti M; Manfreda V; Silvaggio D; Tartaglia C; Roberto D; Campione E; Bianchi L
Expert Opin Biol Ther; 2021 Feb; 21(2):191-200. PubMed ID: 33245022
[No Abstract] [Full Text] [Related]
20. Pathogenesis of psoriasis in the "omic" era. Part IV. Epidemiology, genetics, immunopathogenesis, clinical manifestation and treatment of psoriatic arthritis.
Szczerkowska-Dobosz A; Krasowska D; Bartosińska J; Stawczyk-Macieja M; Walczak A; Owczarczyk-Saczonek A; Reich A; Batycka-Baran A; Czajkowski R; Dobrucki IT; Dobrucki LW; Górecka-Sokołowska M; Janaszak-Jasiecka A; Kalinowski L; Nowicki RJ; Płoska A; Purzycka-Bohdan D; Radulska A; Reszka E; Samotij D; Siekierzycka A; Slominski AT; Slominski RM; Sobalska-Kwapis M; Strapagiel D; Szczęch J; Żmijewski MA; Nedoszytko B
Postepy Dermatol Alergol; 2020 Oct; 37(5):625-634. PubMed ID: 33239999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
